Robinson v. Ortho-McNeil Pharmaceutical, Inc.

533 F. Supp. 2d 838, 2008 U.S. Dist. LEXIS 12119, 2008 WL 344559
CourtDistrict Court, S.D. Illinois
DecidedJanuary 9, 2008
DocketCivil 07-869-GPM
StatusPublished
Cited by4 cases

This text of 533 F. Supp. 2d 838 (Robinson v. Ortho-McNeil Pharmaceutical, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Robinson v. Ortho-McNeil Pharmaceutical, Inc., 533 F. Supp. 2d 838, 2008 U.S. Dist. LEXIS 12119, 2008 WL 344559 (S.D. Ill. 2008).

Opinion

MEMORANDUM AND ORDER

MURPHY, District Judge.

This matter is before the Court on a motion for remand to state court for lack of subject matter jurisdiction (Doc. 9). This action, which was filed originally in the Circuit Court of the Twentieth Judicial Circuit, St. Clair County, Illinois, on November 1, 2007, alleges that Plaintiffs Latoya Robinson, Angela Gourley, Keisha Lewis, Kim Musskopf, Felicia Reed, and Felicia Williams suffered personal injuries *840 as a result of using Ortho Evra, a trans-dermal contraceptive device. They assert claims for strict liability, breach of implied and express warranties, violations of the Illinois Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505/1— 505/12, fraud, and negligence against the makers of Ortho Evra, Defendants Ortho-McNeil Pharmaceutical, Inc., (“Ortho-McNeil”) Johnson & Johnson, (“J & J”) and Johnson & Johnson Pharmaceutical Research and Development, LLC (“J & J Pharmaceutical”). They also assert claims for strict liability, breach of implied warranties, negligence, and statutory consumer fraud against certain pharmacies from which they purchased Ortho Evra, specifically, Defendants American Drug Stores, Inc., (“Oseo Drug”) Walgreen Company (“Walgreens”), B & D Pharmacy, Inc., (“B & D”) and Rite Aid Corporation (“Rite Aid”). Plaintiffs Anthony Robinson, Keith Musskopf, and Ayinde Williams, who are married to, respectively, Latoya Robinson, Kim Musskopf, and Felicia Williams, assert derivative claims for loss of consortium.

On December 17, 2007, OrthoMcNeil, J & J, and J & J Pharmaceutical removed the case from state court to this Court, asserting federal subject matter jurisdiction on the basis of diversity of citizenship, which requires, of course, that the parties to a case be of completely diverse state citizenship, that is, no plaintiff may be a citizen of the same state as any defendant, and that the amount in controversy exceed $75,000, exclusive of interest and costs. See 28 U.S.C. § 1332(a)(1); Cassens v. Cassens, 430 F.Supp.2d 830, 832-33 (S.D.Ill.2006). Although it appears from the record that the jurisdictional amount is satisfied in this case, see Yount v. Shashek, 472 F.Supp.2d 1055, 1066 (S.D.Ill.2006); Fields v. Jay Henges Enters., Inc., Civil No. 06-323-GPM, 2006 WL 1875457, at *3-5 (S.D.Ill. June 30, 2006), diversity of citizenship is not complete. Latoya and Anthony Robinson are citizens of Wisconsin, Angela Gourley is a citizen of Kansas, and Felicia and Ayinde Williams are citizens of New York. OrthoMcNeil is a corporation incorporated under Delaware law with its principal place of business in New Jersey, and therefore is a citizen of Delaware and New Jersey for diversity purposes, while J & J, as a corporation incorporated under New Jersey law with its principal place of business in New Jersey, is a New Jersey citizen. See 28 U.S.C. § 1332(c)(1); Lyerla v. Amco Ins. Co., 461 F.Supp.2d 834, 836 (S.D.Ill.2006). J & J Pharmaceutical is a limited liability company the sole member of which is Ortho-McNeil and therefore is a citizen of Delaware and New Jersey. See McNichols v. Johnson & Johnson, 461 F.Supp.2d 736, 738 n. 1 (S.D.Ill.2006). Keisha Lewis, Kim and Keith Musskopf, and Felicia Reed are citizens of Illinois, as are Oseo Drug, Walgreens, B & D, and Rite Aid.

The removing Defendants contend that diversity of citizenship is complete in this case because the non-diverse Defendants have been fraudulently joined to defeat diversity jurisdiction, that is, there is no possibility that Plaintiffs can establish claims for relief against the non-diverse Defendants under applicable state law. See Phillips v. Howmedica Osteonics Corp., Civil No. 07-833-GPM, 2007 WL 4441228, at *2 (S.D.Ill. Dec. 17, 2007); Mills v. Martin & Bayley, Inc., Civil No. 05-888-GPM, 2007 WL 2789431, at *2 (S.D.Ill. Sept. 21, 2007); Bavone v. Eli Lilly & Co., Civil No. 06-153-GPM, 2006 WL 1096280, at *2 (S.D.Ill. Apr. 25, 2006). Additionally, the removing Defendants request that the Court stay these proceedings so that a determination as to the existence of federal subject matter jurisdiction in this case can be made by the United States District Court for the *841 Northern District of Ohio, where the Judicial Panel on Multidistrict Litigation has established a multidistrict litigation (“MDL”) proceeding for the purpose of conducting coordinated or consolidated pretrial proceedings in cases involving injuries allegedly caused by Ortho Evra. With respect to the removing Defendants’ request for a stay, it generally is not the Court’s practice to allow cases in which the existence of subject matter jurisdiction is seriously at issue to remain pending long in federal court. The legal questions presented by the instant motion for remand are hardly novel ones for the Court, and they are quite as susceptible of resolution here as they are in the MDL court. See Weese v. Union Carbide Corp., Civil No. 07-581-GPM, 2007 WL 2908014, at *1 (S.D.Ill. Oct.3, 2007) (quoting Conroy v. Fresh Del Monte Produce, Inc., 325 F.Supp.2d 1049, 1054 (N.D.Cal.2004)) (holding that it would be “judicially inefficient” to stay proceedings so that a motion for remand could be resolved by a transferee court, given that “[tjhis Court is as qualified to evaluate the factors establishing federal jurisdiction as any other federal court.”).

Turning then to the merits of Plaintiffs’ motion for remand, the primary argument for fraudulent joinder proffered by the removing Defendants is that Plaintiffs’ claims against the diversity-defeating Defendants are precluded under Illinois law by the so-called “learned intermediary” doctrine. 1 As adopted in Illinois in Kirk v. Michael Reese Hospital & Medical Center, 117 Ill.2d 507, 111 Ill.Dec. 944, 513 N.E.2d 387 (1987), the doctrine provides generally that, “where prescription drugs are concerned, the manufacturer’s duty to warn is limited to an obligation to advise the prescribing physician of any potential dangers that may result from the drug’s use. This special standard for prescription drugs is an ... exception to the ... general rule that one who markets goods must warn foreseeable ultimate users of dangers inherent in his products.” Id. at 392 (quoting Stone v. Smith, Kline & French Labs., 731 F.2d 1575, 1579 (11th Cir.1984)). “Prescription drugs are likely to be complex medicines, esoteric in formula and varied in effect. As a medical expert, the prescribing physician can take into account the propensities of the drug as well as the susceptibilities of his patient. His is the task of weighing the benefits of any medication against its potential dangers.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

V. v. Meta Platforms, Inc.
D. Connecticut, 2023
Halliburton v. Johnson & Johnson
983 F. Supp. 2d 1355 (W.D. Oklahoma, 2013)
Reeves v. Pfizer, Inc.
880 F. Supp. 2d 926 (S.D. Illinois, 2012)
Hill v. C.R. Bard, Inc.
582 F. Supp. 2d 1041 (C.D. Illinois, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
533 F. Supp. 2d 838, 2008 U.S. Dist. LEXIS 12119, 2008 WL 344559, Counsel Stack Legal Research, https://law.counselstack.com/opinion/robinson-v-ortho-mcneil-pharmaceutical-inc-ilsd-2008.